115 related articles for article (PubMed ID: 38319154)
1. Age-related phenotypes in breast cancer: A population-based study.
Svanøe AA; Humlevik ROC; Knutsvik G; Sæle AKM; Askeland C; Ingebriktsen LM; Hugaas U; Kvamme AB; Tegnander AF; Krüger K; Davidsen B; Hoivik EA; Aas T; Stefansson IM; Akslen LA; Wik E
Int J Cancer; 2024 Jun; 154(11):2014-2024. PubMed ID: 38319154
[TBL] [Abstract][Full Text] [Related]
2. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer.
Kilickap S; Kaya Y; Yucel B; Tuncer E; Babacan NA; Elagoz S
Asian Pac J Cancer Prev; 2014; 15(3):1381-5. PubMed ID: 24606469
[TBL] [Abstract][Full Text] [Related]
3. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
Shokouh TZ; Ezatollah A; Barand P
Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
[TBL] [Abstract][Full Text] [Related]
5. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
6. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
8. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
9. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
[TBL] [Abstract][Full Text] [Related]
10. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
11. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
12. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
13. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
14. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
15. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.
Elidrissi Errahhali M; Elidrissi Errahhali M; Ouarzane M; El Harroudi T; Afqir S; Bellaoui M
BMC Womens Health; 2017 Jan; 17(1):3. PubMed ID: 28068979
[TBL] [Abstract][Full Text] [Related]
16. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients.
de Kruijf EM; Bastiaannet E; Rubertá F; de Craen AJ; Kuppen PJ; Smit VT; van de Velde CJ; Liefers GJ
Mol Oncol; 2014 Jul; 8(5):1014-25. PubMed ID: 24767310
[TBL] [Abstract][Full Text] [Related]
17. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
18. Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya.
Sawe RT; Mining SK; Ofulla AV; Patel K; Guyah B; Chumba D; Prosperi JR; Kerper M; Shi Z; Sandoval-Cooper M; Taylor K; Badve S; Stack MS; Littlepage LE
Trop Med Health; 2017; 45():19. PubMed ID: 28794686
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
20. QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas.
Knutsvik G; Collett K; Arnes J; Akslen LA; Stefansson IM
Mod Pathol; 2016 Dec; 29(12):1485-1491. PubMed ID: 27562495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
